ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 149 filers reported holding ASCENDIS PHARMA A/S in Q1 2020. The put-call ratio across all filers is 0.46 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $549,000 | +19.3% | 3,443 | -1.6% | 0.06% | +22.0% |
| Q2 2021 | $460,000 | +6.7% | 3,498 | +4.5% | 0.05% | -21.9% |
| Q1 2021 | $431,000 | +1.2% | 3,346 | +31.1% | 0.06% | -15.8% |
| Q4 2020 | $426,000 | +55.5% | 2,552 | +43.6% | 0.08% | +33.3% |
| Q3 2020 | $274,000 | +9.2% | 1,777 | -0.7% | 0.06% | +5.6% |
| Q2 2020 | $251,000 | +20.7% | 1,789 | +15.5% | 0.05% | -1.8% |
| Q1 2020 | $208,000 | – | 1,549 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
| Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
| Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
| Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
| Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
| Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
| Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
| DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
| ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
| Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |